Zacks Investment Research upgraded shares of Evolent Health (NYSE:EVH) from a hold rating to a buy rating in a report published on Tuesday morning. Zacks Investment Research currently has $27.00 price target on the technology company’s stock.

According to Zacks, “Evolent Health, Inc. is involved in the healthcare delivery and payment markets. The company provides technology-enabled services platform for providers to transition their organization in value-based payment models. Evolent Health, Inc. is based in Arlington, Virginia. “

A number of other equities analysts have also recently weighed in on the stock. Cantor Fitzgerald reissued a buy rating and set a $37.00 price target on shares of Evolent Health in a research report on Wednesday, September 12th. Jefferies Financial Group reaffirmed a buy rating and issued a $25.00 price objective on shares of Evolent Health in a research report on Tuesday, August 7th. KeyCorp boosted their price objective on shares of Evolent Health from $26.00 to $28.00 and gave the company an overweight rating in a research report on Monday, August 20th. ValuEngine cut shares of Evolent Health from a strong-buy rating to a buy rating in a research report on Thursday, November 1st. Finally, Piper Jaffray Companies reaffirmed an overweight rating and issued a $34.00 price objective on shares of Evolent Health in a research report on Wednesday, November 7th. Thirteen analysts have rated the stock with a buy rating, Evolent Health presently has a consensus rating of Buy and a consensus price target of $31.82.

Shares of NYSE EVH opened at $20.80 on Tuesday. The firm has a market cap of $1.82 billion, a PE ratio of -29.71 and a beta of 1.54. Evolent Health has a twelve month low of $12.30 and a twelve month high of $29.05. The company has a current ratio of 2.50, a quick ratio of 2.50 and a debt-to-equity ratio of 0.12.

Evolent Health (NYSE:EVH) last announced its quarterly earnings results on Tuesday, November 6th. The technology company reported ($0.04) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.11) by $0.07. The company had revenue of $150.16 million for the quarter, compared to analysts’ expectations of $142.94 million. Evolent Health had a negative net margin of 9.05% and a negative return on equity of 2.18%. The business’s quarterly revenue was up 38.6% compared to the same quarter last year. During the same period last year, the firm posted ($0.18) earnings per share. As a group, equities analysts anticipate that Evolent Health will post -0.33 earnings per share for the current fiscal year.

In other Evolent Health news, General Counsel Jonathan Weinberg sold 15,000 shares of Evolent Health stock in a transaction on Thursday, September 13th. The shares were sold at an average price of $27.12, for a total value of $406,800.00. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, COO Thomas Peterson III sold 70,000 shares of Evolent Health stock in a transaction on Thursday, September 13th. The shares were sold at an average price of $27.50, for a total transaction of $1,925,000.00. The disclosure for this sale can be found here. 4.82% of the stock is currently owned by insiders.

A number of hedge funds have recently modified their holdings of EVH. NumerixS Investment Technologies Inc acquired a new stake in Evolent Health in the 2nd quarter valued at $105,000. DekaBank Deutsche Girozentrale increased its stake in shares of Evolent Health by 235.4% during the 3rd quarter. DekaBank Deutsche Girozentrale now owns 6,205 shares of the technology company’s stock worth $156,000 after purchasing an additional 4,355 shares during the last quarter. Public Employees Retirement Association of Colorado increased its stake in shares of Evolent Health by 106.3% during the 3rd quarter. Public Employees Retirement Association of Colorado now owns 6,904 shares of the technology company’s stock worth $196,000 after purchasing an additional 3,557 shares during the last quarter. Jane Street Group LLC acquired a new position in shares of Evolent Health during the 3rd quarter worth about $205,000. Finally, Paloma Partners Management Co acquired a new position in shares of Evolent Health during the 2nd quarter worth about $209,000.

About Evolent Health

Evolent Health, Inc, through its subsidiary, Evolent Health LLC, provides health care delivery and payment solutions in the United States. The company operates as a managed services firm that supports health systems and physician organizations in migration toward value-based care and population health management.

Featured Story: Understanding each part of a balance sheet

Get a free copy of the Zacks research report on Evolent Health (EVH)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Evolent Health (NYSE:EVH)

Receive News & Ratings for Evolent Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evolent Health and related companies with MarketBeat.com's FREE daily email newsletter.